Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 17/20 | 0.64 |
| ▸ | SCD | O00767 | 8/20 | 0.52 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.48 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.48 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423293 | 0.89 | SCD5 (0.59) | SCD5SCDSTIM1ORAI1ORAI3 | |
| SCHEMBL4425839 | 0.83 | STIM1 (0.65) | SCD5SCDSTIM1ORAI1ORAI3 | |
| SCHEMBL759769 | 0.80 | STIM1 (0.73) | SCD5STIM1ORAI1ORAI3SMN1; SMN2 | |
| SCHEMBL4434159 | 0.80 | SCD5 (0.50) | SCD5SCDSMN1; SMN2 | |
| SCHEMBL15190572 | 0.79 | SCD5 (0.61) | SCD5SCDSMN1; SMN2 | |
| SCHEMBL21523680 | 0.78 | SCD5 (1.00) | SCD5SCDSMN1; SMN2CYP2C8CYP2B6 | |
| SCHEMBL4423566 | 0.78 | SCD5 (0.55) | SCD5SCDSMN1; SMN2 | |
| SCHEMBL21535832 | 0.78 | SCD5 (0.78) | SCD5SCDSMN1; SMN2 | |
| SCHEMBL14887748 | 0.77 | ITGB1 (0.48) | SMN1; SMN2 | |
| SCHEMBL2724122 | 0.77 | MAPT (0.64) | SCD5SCDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | claimed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | claimed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| WO-2012052459-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | NLRP3, IL33, IL5 | SCD5 2471/4885SCD 2487/4885STIM1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.